CARGO Therapeutics, Inc. (CRGX)
Market Cap | 165.24M |
Revenue (ttm) | n/a |
Net Income (ttm) | -154.14M |
Shares Out | 46.03M |
EPS (ttm) | -4.01 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 375,528 |
Open | 3.400 |
Previous Close | 3.480 |
Day's Range | 3.400 - 3.600 |
52-Week Range | 3.000 - 33.920 |
Beta | n/a |
Analysts | Hold |
Price Target | 4.67 (+30.08%) |
Earnings Date | Mar 20, 2025 |
About CRGX
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, In... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CRGX stock is "Hold." The 12-month stock price forecast is $4.67, which is an increase of 30.08% from the latest price.
News

Bronstein, Gewirtz & Grossman, LLC Encourages CARGO Therapeutics, Inc. (CRGX) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company")...

The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 11, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Th...

Bronstein, Gewirtz & Grossman, LLC Is Investigating CARGO Therapeutics, Inc. (CRGX) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company")...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CARGO Therapeutics, Inc. (CRGX) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company")...

Bronstein, Gewirtz & Grossman, LLC Encourages CARGO Therapeutics, Inc. (CRGX) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CARGO Therapeutics, Inc. (CRGX) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

CRGX Investors Have Opportunity to Join CARGO Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES , Feb. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, I...

CARGO Therapeutics, Inc. (CRGX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

Bronstein, Gewirtz & Grossman, LLC Is Investigating CARGO Therapeutics, Inc. (CRGX) And Encourages Investors to Connect
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CARGO Therapeutics, Inc. (CRGX) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

Bronstein, Gewirtz & Grossman, LLC Encourages CARGO Therapeutics, Inc. (CRGX) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CARGO Therapeutics, Inc. (CRGX) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CARGO Therapeutics, Inc. (CRGX) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX
LOS ANGELES , Jan. 30, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ: CRGX) for...

Bronstein, Gewirtz & Grossman, LLC Is Investigating CARGO Therapeutics, Inc. (CRGX) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") ...

The Schall Law Firm Urges Shareholders With Losses To Join An Investigation Into CARGO Therapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO The...

CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel) 1 ; Company believes results do not support a competitive benefit-risk profile for patients. CARGO ...

CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.

CARGO Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma

CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) - - Completed $110 million private placement equity fina...

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
– Financing includes participation from new and existing investors – – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND...

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) (CRG-022); Currently on-track for interim results exp...

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – – Appoin...